Samsung Biologics Co Ltd
KRX:207940
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.8T KRW | 30.5 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.6B USD | 14.9 | ||
US |
Danaher Corp
NYSE:DHR
|
195.1B USD | 8 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 13.5 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.4B USD | 10.3 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.2B CHF | 16.3 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 15.3 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.6B USD | 12.1 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.7B USD | 23.1 | ||
US |
Waters Corp
NYSE:WAT
|
21.5B USD | 13.3 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.1B EUR | 17.5 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.